Navigation Links
Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohn's Disease
Date:8/21/2013

inical remission at week 52, compared to 8.7 percent of patients receiving placebo (p=0.008, p=0.001, respectively). 31.4 percent and 45.2 percent of patients on oral glucocorticoids at baseline treated with vedolizumab every eight and four weeks, respectively, achieved glucocorticoid-free remission at week 52, compared to 13.9 percent of patients receiving placebo (p=0.01, p<0.001, respectively).

The safety population in GEMINI I comprised 895 patients for weeks 0-52. The most common adverse events reported in the 620-patient vedolizumab arm (greater than or equal to 9.0 percent) were ulcerative colitis, headache, nasopharyngitis and arthralgia. The most common adverse events reported in the 275-patient placebo arm (˃9.0 percent) were ulcerative colitis, headache, nasopharyngitis and arthralgia. No increase in rates of serious, opportunistic or enteric infections was observed with vedolizumab. One death occurred in a 66-yr-old man who received one induction dose of vedolizumab and died 14 days later from acute coronary syndrome.

"Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease"
The publication, titled "Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease," discusses findings from GEMINI II, a Phase 3, randomized, parallel-group, double-blind, placebo-controlled induction and maintenance study designed to assess the efficacy and safety of vedolizumab as a therapy for adults with moderately to severely active Crohn's disease (CD), in whom one prior therapy had failed. In the induction phase, the co-primary endpoints were clinical remission and CDAI-100 response at week six, while the secondary endpoint was mean change in serum C-reactive protein (CRP) levels from baseline to week six. The ITT population comprised 368 patients, with an additional 747 patients receiving open-label vedolizumab. Of the 368, 220 received vedolizumab 300 mg IV and 148 received placebo. Approximately 50 percent of the ITT popula
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. 1st Case Report of Using Single-Site Cannulation ECMO to Treat SynCardia Total Artificial Heart Patient Published in Journal of Cardiothoracic Surgery
2. Mechanism for Cardiac Effects of Trevena Angiotensin Receptor Biased Ligands Examined in Published Study
3. Leadership Through Research Collaboration Is Reflected In Articles Published In Alzheimers Association Journal
4. Depression Study Published on BCM-95 Curcumin
5. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
6. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
7. BioElectronics New Patent Published
8. Benefits of Using Hologics Breast Tomosynthesis Mammography Technology Supported in Published Italian Study
9. Clinical Results for Orameds Oral Diabetes Treatment Published in Peer Reviewed Journal PLOS ONE
10. Study Published in European Radiology Further Supports the Use of Hologics Breast Tomosynthesis in Cancer Screening in Practices Using Double Reads
11. Data on SEEKs Novel Immunotherapy for HIV Published in Virology Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , September 23, 2014 ... has announced the addition of the  "Large ... to their offering.  ,     ... drug delivery market holds significant potential for ... vials and painful needles to the modern-day ...
(Date:9/23/2014)... SAN FRANCISCO , Sept. 23, 2014  SiteOne ... round of equity financing. Led by Sears Capital Management ... and Joe Zakrzewski , the $1.5 million financing ... inhibitor program for pain and to further develop its ... other pain indications. In conjunction with the ...
(Date:9/23/2014)... September 23, 2014 According ... by Product (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave), ... Orthopedics) - Global Forecasts to 2019", published by ... forecast period of 2014 to 2019. The market ... at CAGR of 9.6% from 2014 to 2019. ...
Breaking Medicine Technology:Large Volume Wearable Injectors - 2nd Edition 2Large Volume Wearable Injectors - 2nd Edition 3Large Volume Wearable Injectors - 2nd Edition 4Large Volume Wearable Injectors - 2nd Edition 5SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 4
... Oct. 12, 2011 Reportlinker.com announces that ... in its catalogue: ... Region 2010-2014 ... the Peripheral Vascular Devices market in the ...
... (NYSE: BSX ) will webcast its conference call ... 2011 on Thursday, October 20, at 8:00 a.m. ET. ... becomes Boston Scientific,s Chief Executive Officer on October 17, and ... A live webcast of the conference call will be ...
Cached Medicine Technology:Peripheral Vascular Device Market in the APAC Region 2010-2014 2Boston Scientific To Webcast Conference Call Discussing Third Quarter 2011 Financial Results 2
(Date:9/23/2014)... (PRWEB) September 23, 2014 AttorneyOne.com, a ... all the latest information from the FDA on ... 5, that its Private Label Jalapeno Bagels are recalled ... stones. Publix Jalapeno Bagels were sold in ... department. , Taking into consideration the latest developments, ...
(Date:9/23/2014)... 23, 2014 (HealthDay News) -- A test used to diagnose ... where certain lung infections are more common, a new analysis ... is through the use of what,s known as functional imaging. ... FDG-PET is used, according to the study authors. Cancerous ... parts of the lungs that don,t have cancer, according ...
(Date:9/23/2014)... Grinnell Mutual seeks submissions from the public ... Working Together Making It Better will provide grants ... positively impacting their communities. , “So many people ... a better places,” said Grinnell Mutual ... “Their leadership—as coaches, as volunteers, as mentors—help to ...
(Date:9/23/2014)... who are already obese as teenagers could grow up ... peers of normal weight. So says Petter Lundborg of ... Rooth of Linneas University and Lund University, all in ... United Kingdom and the United States, and the results ... , The researchers analyzed large-scale data of 145,193 Swedish-born ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 ... allergic rhinitis (AR) is highly fragmented, with ... SIT formulations available, under different regulatory restrictions, ... markets. Europe has the most developed market, ... and allergen immunotherapy tablets (AITs) all being ...
Breaking Medicine News(10 mins):Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2Health News:Grinnell Mutual Invites Submissions for Innovative, Collaborative Local Projects in Its Second Annual Working Together Making It Better Promotion 2Health News:Note to young men: Fat doesn't pay 2Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 4
... and community for decades, PHILADELPHIA, Nov. 11 ... leading health insurer, turns 70,years old. While health ... 1938, experts agree that access to affordable,quality health ... was a key,consideration when millions cast their vote ...
... Introducing ReBound(TM) the Revolution in Thermotherapy, ALAMEDA, ... and,ReGear Life Sciences announced today the introduction of ... to treat pain, muscle,spasms, and joint contractures using ... for providing state-of-the-art injury treatment systems,to the physical ...
... triglycerides throughout the body , , TUESDAY, Nov. 11 (HealthDay ... the risk of high blood pressure in women who ... of a new study by U.S. researchers who analyzed ... Study. , Lipoprotein particles carry cholesterol and triglycerides throughout ...
... walls as thick as that of a middle-aged person ... days are 13 going on 45, at least when ... presented Tuesday at the American Heart Association,s annual scientific ... representative of someone three decades older. , "These data ...
... NEW YORK, Nov. 11 Today, the ... the results of a,nationwide survey on the ... "Unfortunately, APIC failed to connect the dots,",says ... to Reduce Infection,Deaths (RID). "The new data ...
... 11 Pam Kreager, Director of,Clinical Quality ... Term,Care Group, Inc. (LTCG), has been elected ... (LTCIF). The Long Term Care International Forum,( ... is to promote,efficiency, effectiveness and high standards ...
Cached Medicine News:Health News:Independence Blue Cross Celebrates 70 Years Of Service In Southeastern Pennsylvania 2Health News:Independence Blue Cross Celebrates 70 Years Of Service In Southeastern Pennsylvania 3Health News:Independence Blue Cross Celebrates 70 Years Of Service In Southeastern Pennsylvania 4Health News:Independence Blue Cross Celebrates 70 Years Of Service In Southeastern Pennsylvania 5Health News:Game Ready(TM) and ReGear Life Sciences(TM) Bring Innovative New Heat Therapy to Market 2Health News:Game Ready(TM) and ReGear Life Sciences(TM) Bring Innovative New Heat Therapy to Market 3Health News:Lipoprotein Levels May Predict Women's Hypertension Risk 2Health News:Obese Kids Have Old Arteries 2Health News:Obese Kids Have Old Arteries 3Health News:APIC Covers Up Extent and Causes of Deadly C. diff 2Health News:Long Term Care International Forum names LTCG's Pam Kreager as President 2
The original battery-operated suction and irrigation system features a new ergonomic hand piece and superior performance characteristics that have increased the overall flow rate....
... of both worlds, the PeaceKeeper 20 ... latest addition to the Wet-Field comprehensive ... instruments for ophthalmic surgery. Combining highly ... and backflush functionality in a single ...
...
...
Medicine Products: